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Abstract
Background: Infant HIV infection is associated with delayed milestone attainment. The extent to which effective
antiretroviral therapy (ART) prevents these delays is not well defined.
Methods: Ages at attainment of milestones were compared between HIV-infected (initiated ART by age <5 months),
and HIV-unexposed uninfected (HUU) infants. Kaplan Meier analyses were used to estimate and compare (log-rank
tests) ages at milestones between groups. Adjusted analyses were performed using Cox proportional hazards models.
Results: Seventy-three HIV-infected on ART (median enrollment age 3.7 months) and 92 HUU infants (median
enrollment age 1.6 months) were followed prospectively. HIV-infected infants on ART had delays in developmental
milestone attainment compared to HUU: median age at attainment of sitting with support, sitting unsupported,
walking with support, walking unsupported, monosyllabic speech and throwing toys were each delayed (all p-values
<0.0005). Compared with HUU, the subset of HIV-infected infants with both virologic suppression and immune
recovery at 6 months had delays for speech (delay: 2.0 months; P = 0.0002) and trend to later walking unsupported. Among
HIV-infected infants with poor 6-month post-ART responses (lacking viral suppression and immune recovery) there were
greater delays versus HUU for: walking unsupported (delay: 4.0 months; P = 0.0001) and speech (delay: 5.0 months; P< 0.
0001).
Conclusions: HIV infected infants with viral suppression on ART had better recovery of developmental milestones than
those without suppression, however, deficits persisted compared to uninfected infants. Earlier ART may be required for
optimized cognitive outcomes in perinatally HIV-infected infants.
Trial registration: NCT00428116; January 22, 2007.
Keywords: Antiretroviral therapy, HIV, Infant, Sub-Saharan Africa, Neurodevelopment, Early antiretroviral therapy
Background
Ninety percent of HIV-infected infants worldwide are
born in sub-Saharan Africa, where opportunities for
early HIV diagnosis are frequently missed [1–4]. Infant
HIV diagnosis often does not occur until after onset of
symptomatic HIV [5–7]. HIV-infected infants have a
particularly high early viral burden [8] and rapid disease
progression [9], and the window of opportunity to
minimize the HIV reservoir in the brain is likely short.
Early pre-ART disease progression may be associated
with neuronal damage that is not salvageable. Con-
versely, effective ART may provide benefit, if initiated
very early in infancy. In cohorts of infants with no or
limited access to early ART, 30–36% and 26–36% had
mental and motor delays, respectively [10–12].
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There are few data on neurodevelopmental outcomes
of early ART-treated infants in Africa. In ART-treated
HIV-infected children in the US, early (prior to age
5 years) plasma viral suppression [13] was associated
with higher school-age IQ scores, supporting the hy-
pothesis that effective ART in infancy may improve neu-
rocognition; however, in this study children with better
virologic responses to ART still had scores well below
national norms. In older US cohorts, children with no
history of symptomatic HIV disease had similar neuro-
cognitive outcomes compared with HIV-exposed unin-
fected peers [14–17], but these studies potentially
included an elite subset of surviving HIV-infected
children.
Recent data from the South African CHER study sug-
gests that early ART is broadly beneficial in preserving
neurocognitive function. In this randomized trial,
asymptomatic infants without immunosuppression who
received ART by 6–12 weeks of age had similar mental,
social and locomotor scores as HIV-uninfected infants at
11 months of age [18]. In the same study, infants who
received deferred ART (until symptomatic or meeting
CD4 treatment criteria at the time) had lower locomotor
scores, suggesting early HIV disease progression com-
promised outcomes.
For HIV-infected infants born in settings in which
symptomatic HIV prior to ART is the norm, it is
unknown whether an effective response to ART dur-
ing early infancy can lead to comparable neurodeve-
lopmental outcomes as HIV-uninfected peers. We
previously reported that greater CD4% gain over
6 months on ART was associated with earlier age at
walking and speech in early treated Kenyan infants,
a majority of whom who presented with symptom-
atic HIV disease at ART [19]. Here, we present data
comparing this cohort of HIV-infected infants to
HUU infants with a similar age range. We hypothe-
sized that these infants would have persistent differ-
ences in milestone attainment compared with HUU




HIV-infected infants participated in a randomized clin-
ical trial (Optimizing Pediatric HIV-1 Therapy 03
(OPH03) with a 2-year pre-randomization period, in
which infants attended monthly study visits, with data
collection, prior to randomization (NCT00428116) [20].
As described previously, infants were identified at either
maternal child health clinics or hospital wards in
Nairobi. Enrollment eligibility criteria were HIV DNA
PCR positive with confirmation, age <5 months, and no
previous receipt of antiretroviral therapy, with the
exception of prophylaxis for prevention of mother to
child transmission (PMTCT). Following enrollment and
adherence counseling, ART was initiated, generally
within 2 weeks. Infants with no prior exposure to nevira-
pine (NVP) for PMTCT received a first-line regimen
consisting of NVP plus 2 nucleoside reverse transcript-
ase inhibitors (generally zidovudine and lamivudine),
and infants with prior NVP exposure received a first-line
regimen consisting of this backbone, plus ritonavir-
boosted lopinavir (LPV/r). Nearly all infants had re-
ceived trimethoprim-sulfamethoxazole (cotrimoxazole)
prophylaxis prior to or at enrollment. HIV-infected in-
fants were enrolled from 2007 to 2009.
From 2011 to 2013, HIV-unexposed uninfected (HUU)
infants were identified following routine HIV-testing of-
fered to pregnant mothers at the Mathare North MCH
Clinic in Nairobi. HIV seronegative mothers were re-
cruited for infant participation in a 2-year cohort study
involving similar study visit schedules as in the OPH03
study. Enrollment eligibility criteria were 1) age 0–4.5
months, 2) biological mother and infant with HIV-
negative status, and 3) mother planned to reside within
Nairobi for at least 2 years. Mother and infant HIV sta-
tus were verified using an HIV rapid antibody test at en-
rollment. Maternal HIV-negative status was confirmed
at 12 and 24 months during follow-up.
Following standardized questionnaires on sociodemo-
graphic and medical history, infants received a physical
examination at enrollment and a blood sample was col-
lected for CD4 testing and for HIV-infected infants, vi-
rologic testing. During follow-up, infants attended
monthly visits at which a physical exam was adminis-
tered with blood collection at 1-month and 3-monthly
thereafter for HIV-positive infants, and 6-monthly for
HUU infants.
Developmental milestones
Developmental milestones were assessed at enrollment
and at monthly visits for the duration of follow-up. Mile-
stones were adapted from the Denver Developmental
Screening Test [21]. The same team of clinical officers
performed study visits and assessed milestones. Care-
givers self-reported the age at which the milestone had
been achieved at monthly visits. Analyses presented here
utilized the self-reported age wherever possible, and an
estimated age (using the date of study visit at which the
milestone was first noted by the clinician) was used in
cases in which the self-reported age was missing. Sensi-
tivity analyses including only the clinician-reported age
gave similar results. Milestones included full neck con-
trol (defined as whether the infants could support his or
her own head) (neck control), sitting with support (de-
fined as whether the child could sit with a straight back
on the caregiver’s lap or on the floor between the
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caregiver’s legs), sitting unsupported (defined as whether
the child could sit on a flat surface or on the caregiver’s
lap without needing support), walking with support (de-
fined as whether the child could walk well with the help
of someone holding one or both hands or when support-
ing self using furniture or a wall), walking unsupported
(defined as whether the child could take a few steps
without needing support), monosyllabic speech (defined
as whether the infant was able to say one-syllable words
or sounds, referring to a specific person or object)
(speech), throwing toys (defined as whether the child
could throw a toy such as a ball while playing), naming
objects (defined as whether the caregiver reported that
the child could point to and name common household
items such as cups or plates). This analysis was focused
primarily on milestones expected to occur within a few
months of the 6-month on-ART visit, namely walking
unsupported and speech.
Laboratory testing
In Nairobi, flow cytometry was performed to obtain en-
rollment and 6-monthly CD4 counts and percentages.
Whole blood specimens were centrifuged using a Ficoll
density gradient to separate plasma, which was cryopre-
served at −70 ° C. Plasma HIV RNA levels were ascer-
tained using the Gen-Probe HIV Viral Load Assay (San
Diego, CA) in Seattle, WA [22]. Blood hemoglobin levels
were assessed in Nairobi.
Statistical analysis
This study was a secondary analysis using data collected
for infants participating in a randomized clinical trial (all
infants with available milestone data were included) and
a comparison group of infants enrolled (N = 100) during
a later timeframe. Z-scores for weight-for-age (WAZ),
height-for-age (HAZ), weight-for-height (WHZ) and
head circumference-for-age (HCZ) were calculated using
the 2006 WHO reference population [23]. Baseline char-
acteristics were compared between HUU and HIV-
infected infants using t-tests for continuous variables
and chi-squared tests or Fisher’s exact tests, as appropri-
ate, for dichotomous variables. Baseline cofactors con-
sidered were infant sex, birth weight, hemoglobin level,
and z-scores for growth parameters, and caregiver age,
marital status, years of education, number of rooms in
the house, and household monthly rent.
Median (50th percentile) and the interquartile range
(IQR) (25th and 75th percentiles) for ages at attainment
of milestones were calculated using Kaplan-Meier sur-
vival methods, with birth as the time origin. Thirty-one
(42.5%) HIV-infected infants and 13 (17.3%) HUU in-
fants already had achieved neck control by the time of
enrollment, and thus the proportion of infants with neck
control by age 5.0 months (the maximum age at
enrollment for these 44 infants) was compared. Age at
attainment of milestones was compared between groups
using log-rank tests for all other milestones. Using this
approach, infants who never achieved a given milestone
contributed to the analysis until they were censored.
Multivariate analyses employed Cox proportional haz-
ards regression. In addition to baseline cofactors listed
above, we evaluated WAZ during ART (6-months post-
start), average monthly change in WAZ, and a dichot-
omous indicator for WAZ < −2 during ART for inclusion
in multivariate models. Cofactors were assessed for asso-
ciation with age at walking unsupported or speech
within either HIV-infected or HUU infants; those with
significance P < 0.05 were evaluated in multivariate mod-
eling. Multivariate models including caregiver education
were also evaluated a priori.
Primary analyses focused on the walking unsupported
and speech milestones. For these analyses, infants with
effective response to ART (defined using virologic, im-
mune, and growth markers) were compared with HUU
infants as a referent. HIV-infected infants with effective
6-month viral, immune, and growth responses were de-
fined as having plasma HIV RNA <1000 HIV-RNA cop-
ies/ml, CD4% ≥25%, and WAZ ≥ −2 at 9 months of age
(approximately 6 months post initiation of ART), re-
spectively. For primary multivariate analysis, the thresh-
old for considering statistical significance utilized a
conservative Bonferroni adjustment for the 6 multiple
comparisons (three groups defined by 6-month virologic,
immune, and growth responses for walking unsupported
and speech). Therefore, P-values <0.008 were considered
statistically significant. Results are also shown for the
comparison of the ineffective ART groups to HUU.
In exploratory analyses, infants with combined 6-
month immune and viral responses to ART were com-
pared with HUU infants. For each of these stratified ana-
lyses, ages of attainment of walking unsupported and
speech for HIV-infected infants with poor immune, viro-
logic, or growth responses, or combined poor immune
and virologic responses were also compared with that
for HUU infants. In addition, exploratory analyses com-
pared age at speech in infants who received LPV/r-based
ART compared with HUU infants.
Statistical analyses were performed using Stata SE, ver-
sion 11.2, College Station, TX.
Results
Enrollment characteristics of HIV-infected and HUU
infants
Ninety-nine HIV-infected infants were enrolled, of
whom 26 died, were lost-to-follow-up or withdrew be-
fore initiating ART and providing milestone data, leaving
73 for these analyses [20] (see Additional file 1: Figure
S1). Among 100 enrolled HUU infants, seven were lost-
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to-follow-up or withdrew prior to providing milestone
data, and one was diagnosed with cerebral palsy and was
excluded from analysis. At enrollment, HIV-infected in-
fants were older than HUU infants (medians, 3.7 vs
1.6 months; P < 0.0001) (Table 1). HIV-infected infants
had lower birth weight (3.1 vs 3.2 kg) P = 0.02), and base-
line WAZ (medians, −2.0 vs −0.2; P < 0.0001), HAZ (me-
dians, −1.9, vs −1.4; P = 0.04), WHZ (medians, −0.6, vs 1.4;
P < 0.0001), and HCZ (medians, −0.5 vs 0.4; P = 0.0002)
compared with HUU infants. HIV-infected infants had a
median CD4 percentage of 18%, 30 (41.1%) were diag-
nosed with WHO Stage 3 or 4 disease, and 38 (52.1%) had
been hospitalized prior to enrollment. Sixty-two of
seventy-three (84.9%) infants had a CD4 percentage below
25%, were diagnosed with WHO Stage 3 or 4 HIV disease,
or both, before starting ART.
The majority of HIV-infected infants (97.3%) and (per
eligibility criteria) all HUU infants were cared for by
their biological mother. The majority of caregivers in
each group of infants were married (78.1% vs 87.9%; P =
0.09). Both groups had similar education levels (medians,
9 vs 9 years; P = 0.3), but HIV-infected had lower
monthly rent levels (medians, 1,500 vs 2,500 KES; P <
0.0001). The majority of infants in each group lived in a
one-room house (76.7% vs 82.4%; P = 0.4).
Delayed milestones in HIV-infected versus HUU infants
We previously reported that prior history of
hospitalization, a WHO Stage 3 or 4 diagnosis, lower
WAZ, HAZ, and WHZ and lower maternal CD4 count
were associated with later age at milestone attainment in
HIV-infected infants [19]. In the present analysis, HUU
Table 1 Summary of baseline characteristics for infants included in analysis
HIV-infected HUU
Na Median (IQR) or N (%) Na Median (IQR) or N (%) P
Infant characteristics
Age at enrollment (months) 73 3.7 (3.1, 4.0) 92 1.6 (0.9, 2.1) <0.0001
Male 73 35 (48.0) 92 53 (57.6) 0.2
Birth weight (kg) 68 3.1 (2.7, 3.4) 92 3.2 (3.0, 3.5) 0.02
Received PMTCT 68 39 (57.4) - - -
Hemoglobin g/dL 73 9.7 (9, 10.9) 79 11.0 (10.2, 12.7) <0.0001
Ever breastfed 64 56 (87.2) 89 89 (100) 0.001b
Infant clinical, immunologic, virologic, and growth status
Ever hospitalized 73 38 (52.1) 92 0 (0) <0.001b
WHO stage 3 or 4 73 30 (41.1) - - -
Plasma HIV RNA (log10 copies/mL) 69 6.5 (6.0, 7.0) - - -
CD4% 73 18 (14, 24) 80 42 (35, 47) <0.0001
CD4 count (cells/mL) 73 1,311 (801, 1,760) 80 2,515 (2,011, 3,244) <0.0001
WAZ 73 −2.0 (−3.3, −0.9) 92 −0.2 (−1.0, 0.3) <0.0001
HAZ 73 −1.9 (−3.0, −0.8) 92 −1.4 (−2.4, −0.4) 0.04
WHZ 73 −0.6 (−1.6, 0.6) 92 1.4 (0.2, 2.3) <0.0001
HCZ 73 −0.5 (−1.3, 0.5) 92 0.4 (−0.5, 1.1) 0.0002
Primary caregiver characteristics
Biological mother 73 71 (97.3) 92 92 (100) -
Age (years) 72 26 (22, 30) 89 24 (22, 27) 0.1
Married 73 57 (78.1) 91 80 (87.9) 0.09
Education (years) 66 9 (8, 11) 90 9 (8, 12) 0.3
One-room house 73 56 (76.7) 91 75 (82.4) 0.4
Household monthly rent (KES) 69 1,500 (1,000, 2,500) 88 2,500 (2,000, 3,500) <0.0001
Maternal CD4 count (cells/mm3) 70 370 (246, 478) - -
HUU HIV-unexposed uninfected, IQR interquartile range, PMTCT prevention of mother-to-child transmission, WHO World Health Organization, WAZ weight-for-age
z-score, HAZ height-for-age z-score, WHZ weight-for-height z-score, HCZ head circumference-for-age z-score, KES Kenyan Shillings
aIncludes infants surviving, or remaining enrolled in the study long enough to define attainment of neck control
bFisher’s exact test
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infants living in a house with >1 room had earlier age at
attainment of milestones (speech, medians, 11 (IQR, 9, 12)
vs 12 (IQR, 11, 13) months; P = 0.02; throwing toys,
medians, 14 (IQR, 13, 15) vs 15 (IQR 14, 16) months; P =
0.02). Infants living in households with higher rent (>1500
KES/month) also had earlier age at throwing toys (medians,
14 (IQR, 14, 16); vs 17 (IQR, 15, 18) months; P = 0.02).
We hypothesized that HIV-infected infants would have
later milestone attainment compared with HUU infants.
In Kaplan-Meier analyses, 82.8% (95% CI, 72.9, 90.6) of
HIV-infected and 96.6% (95% CI, 91.2, 99.1) of HUU in-
fants had neck control by 5 months of age. HIV-infected
infants also had significantly later age at sitting unsup-
ported (medians, 7 vs 6 months; P < 0.0001), walking
unsupported (medians, 15 vs 13 months; P < 0.0001) and
speech (medians, 15 months vs 12; P = 0.0001), com-
pared with HUU infants (Table 2). Age at attainment of
other milestones, including sitting with support, walking
with support, and throwing toys were also significantly
later compared with HUU. Median age at naming ob-
jects was marginally later for HIV-infected and HUU in-
fants, though this did not reach statistical significance
(22 versus 19 months; (P = 0.07).
Growth, immune and virologic responses during ART
were associated with partial improvement for age at
attainment of milestones
At 6 months post-ART start, 28/54 (51.8%) of infants had
viral suppression (plasma HIV RNA <1000 copies/ml), 27
(50.0%) had immune reconstitution (CD4% ≥25), and 38
(70.4%) infants had achieved a WAZ ≥ −2. As would be ex-
pected based on prior studies [13, 24], HIV-infected infants
with poor 6-month viral responses to ART (plasma HIV
RNA ≥1000 copies/ml) had significantly later speech and
walking unsupported milestones than HUU infants (all P-
values ≤0.0001; Table 3 and Fig. 1). These differences
remained significant in analyses adjusted for 6 month post-
ART growth (WAZ< −2) and household rent, (all P-values
<0.005). Results were similar for infants with poor immune
response to ART and underweight (WAZ< −2) at
6-months following start of ART.
We hypothesized that infants with effective responses to
ART (defined by their virologic, immune or growth re-
sponses) would have significant developmental differences
compared with HUU infants. HIV-infected infants with
viral suppression had delayed walking unsupported and
speech compared to HUU (walking median delay, 2 months;
P = 0.0009; speech median delay, 3 months; P <0.0001).
In Cox proportional hazards models adjusted for 6 month
post-ART growth status (WAZ< −2) and household rent,
infants with viral suppression had significantly later speech
(adjusted hazard ratio (aHR), 0.28, 95% confidence interval
(CI), 0.16, 0.46; P < 0.001) and a trend to later walking
unsupported (aHR, 0.58, 95% CI, 0.36, 0.92; P = 0.02, above
the Bonferroni-corrected alpha of 0.008). Infants with
6-month immune reconstitution had delayed speech com-
pared to HUU (aHR, 0.33, 95% CI, 0.21, 0.55; P < 0.001).
Infants with sustained WAZ> −2 at 6 months also had later
speech (P <0.001). Pre-ART WAZ, 6-month change in
WAZ, birth weight, living in a one-room house, and care-
giver education were not included in final models due to
collinearity. In sensitivity analyses, models adjusted for each
of these variables gave similar results.
Eighteen of fifty-four (33.3%) infants had combined
viral suppression and immune reconstitution at 6-
months post-ART. In exploratory analyses, these in-
fants had similar age at walking unsupported (aHR,
0.73, 95% CI 0.43, 1.26; P = 0.3), but had delayed
speech compared with HUU infants (unadjusted me-
dian delay, 2 months; P = 0.0002; aHR, 0.40, 95% CI,
0.23, 0.69; P = 0.001). Infants with both poor viral
suppression and poor immune reconstitution had
even more pronounced delays (walking: median dif-
ference delay, 4 months; P= 0.0001; speech delay, 5 months,
P < 0.0001) compared with HUU infants. These differences
remained in adjusted models (all p-values ≤0.001).
Table 2 Comparison of age at attainment of milestones for HIV-infected infants vs HIV - unexposed uninfected infants using Kaplan
Meier survival analyses
HIV-infected HUU
Events Median (IQR) Months Events Median (IQR) Months Pa
Milestone
Sitting with support 63 5 (5, 6) 91 4 (4, 5) <0.0001
Sitting unsupported 61 7 (6, 7) 88 6 (5, 6) <0.0001
Walking with support 56 9 (10, 12) 77 9 (8, 10) 0.0002
Walking unsupported 54 15 (13, 18) 69 13 (11, 14) <0.0001
Monosyllabic speech 53 15 (13, 17) 72 12 (10, 13) 0.0001
Throwing toys 55 17 (15, 19) 60 15 (14, 16) <0.0001
Naming objects 52 22 (19, 24) 45 19 (18, 23) 0.07
HUU HIV-unexposed uninfected, IQR interquartile range
aLog - rank tests
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HIV-infected infants in this study received LPV/r-based
ART if they had prior exposure to NVP for PMTCT, and we
previously reported that infants receiving LPV/r-based ART
had significantly earlier speech compared with those receiv-
ing NVP-ART [19]. In exploratory analyses, infants receiving
LPV/r-based ART still had significantly later speech than
HUU infants (aHR, 0.37, 95% CI, 0.21, 0.65; P= 0.001).
Discussion
Here we show that early ART-treated HIV-infected infants
had measurable neurodevelopmental differences compared
with HUU infants in the first 2 years of life. These results
are consistent with recent findings from the CHER trial in
South Africa, in which infants randomized to deferred ART
had lower locomotor scores at 11 months of age compared
with HIV-uninfected infants [18]. In addition, a second
South African study found differences in language and
motor scores among HIV-infected infants who had initiated
ART at a mean age of approximately 5 months and were
followed for six months, compared with HIV-exposed
uninfected infants [25]. In contrast to CHER, which did not
find deficits in other domains, we found persistent delays
in speech attainment among early-ART treated infants
compared to HUU, even in the subgroups with evidence of
good ART response with viral suppression, immune recov-
ery and growth. Compared with HUU infants, HIV-infected
infants with both viral suppression and immune reconstitu-
tion had significantly later speech. These results suggest that
among HIV-infected infants who often had HIV symptoms
prior to initiation of ART, neurodevelopmental delays may
not be completely resolved despite effective ART responses.
Data from previous studies suggest a narrow window
of time during infancy in which neurocognitive deficits
due to HIV may be reversed by ART. In the PREDICT
study, asymptomatic children over 1 year of age had no
improvement in neurocognitive outcomes during nearly
3 years of follow-up on ART [26]. A retrospective analysis
including children ages 2–17 years and with CDC Class 1
or 2 disease demonstrated only modest improvement in
vocabulary scores following initiation of PI-based therapy
[27]. In the same study, children with viral suppression at
one-year following combination ART did not demonstrate
better neurocognitive functioning [27]. Thus, among
children over 1 year of age, neurocognitive effects of HIV
may not be reversed by ART in the same way as among
infants receiving ART in the first months of life.
Table 3 Kaplan-Meier (unadjusted) and Cox proportional regression (adjusted) analyses for age at attainment of milestones for HIV-
infected infants stratified by ART responses and ART regimen and compared with HIV-unexposed uninfected infants
Unadjusted b Adjusted c
Na Median (IQR) Months P HR (95% CI) P
Walking unsupported
HUU-reference 69 13 (11, 14)
HIV+, 6-mo VL <1000 c/mL 28 15 (13, 16) 0.0009 0.58 (0.36, 0.92) 0.02*
HIV+, 6-mo VL ≥1000 c/mL 25 16 (13, 20) 0.0001 0.43 (0.24, 0.76) 0.004
HIV+, 6-mo CD4% ≥25% 27 14 (13, 15) 0.02 0.73 (0.46, 1.16) 0.2*
HIV+, 6-mo CD4% <25% 27 17 (13, 20) <0.0001 0.35 (0.19, 0.61) <0.001
HIV+, 6-mo WAZ≥ −2 38 15 (13, 16) 0.001 0.59 (0.39, 0.90) 0.014*
HIV+, 6-mo WAZ < −2 15 17 (13, 22) <0.0001 0.26 (0.13, 0.53) <0.001
Monosyllabic speech
HUU-reference 72 12 (10, 13) - -
HIV+, 6-mo VL <1000 c/mL 28 15 (12, 16) <0.0001 0.28 (0.16, 0.46) <0.001*
HIV+, 6-mo VL ≥1000 c/mL 24 15 (14, 19) <0.0001 0.20 (0.11, 0.36) <0.001
HIV+, 6-mo CD4% ≥25% 27 14 (12, 16) <0.0001 0.33 (0.21, 0.55) <0.001*
HIV+, 6-mo CD4% <25% 26 16 (14, 19) <0.0001 0.14 (0.08, 0.27) <0.001
HIV+, 6-mo WAZ≥ −2 37 14 (13, 16) <0.0001 0.26 (0.16, 0.42) <0.001*
HIV+, 6-mo WAZ < −2 15 16 (15, 19) <0.0001 0.15 (0.07, 0.29) <0.001
HUU HIV-unexposed uninfected, HIV+ HIV-infected, IQR interquartile range, CI confidence interval, VL plasma viral load (HIV RNA), WAZ weight - for - age Z-score
aN, number of events
b Comparison of each group of HIV-infected infants vs HIV-unexposed uninfected infants (HUU) using log - rank tests
c Cox regression analyses adjusted for monthly household rent. For comparisons of effective viral load and CD4%, adjustment was also made for WAZ < −2 at
9 months of age (approximately 6 months after initiating ART)
*Using Bonferroni to account for 6 multiple comparisons, P-values <0.008 were considered statistically significant
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Previous studies have found deficits in language in
HIV-infected children [25, 28–30]. We previously re-
ported that use of LPV/r-based ART was associated with
earlier age for speech in this cohort. Here, we further
show that in spite of benefits for earlier speech in HIV-
infected children receiving LPV/r-based ART, their
speech was still delayed compared to HUU children.
Delays in milestone attainment in spite of systemic
viral suppression or immune reconstitution may reflect
early viral infiltration to the central nervous system or
poor clearance from the CNS following ART. In South
African infants, white matter abnormalities were appar-
ent on magnetic resonance imaging scans in 50% of 44
early treated infants who had suspected HIV-related
neurological disease, many of whom had viral suppres-
sion prior to imaging [31]. Similarly, a case study iden-
tified 4 children with cognitive decline in spite of viral
suppression [32]. Neurocognitive impairment in spite of
effective suppressive ART has also been described in




HIV+, HIV-infected; HUU, HIV-unexposed uninfected; VL, HIV RNA plasma viral 
load; WAZ, weight for age Z-score. 
Fig. 1 Kaplan Meier survival curves comparing probability of walking unsupported and speech between HIV-infected and HIV-unexposed unin-
fected (HUU) infants (stratified by a, virologic response at 6 months post-ART (approximately 9 months of age); b, immune response; c,
growth response)
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attainment in HIV-infected infants may reflect poor
early infant health, which may have delayed physical
and social play activities important for speech and walk-
ing attainment.
Stunting and micronutrient deficiencies are key cofactors
for poor neurodevelopment in the general population [34],
and are common in perinatally HIV-infected children
[35–37]. Poor growth in HIV-infected infants may be
further compounded by the metabolic cost of HIV and
other co-pathogens and chronic immune activation in the
periphery. We previously reported that among HIV-
infected infants, those with lower nutritional status both
prior to ART and during ART had later walking attainment
[19]. Here we show that infants with adequate growth
(WAZ> −2) during ART had a trend for later walking
unsupported and significantly later speech compared with
HUU infants. We found that living in a one-room house
was associated with delayed speech attainment in HUU in-
fants, underscoring the interplay between economic status
and neurodevelopment. Malnutrition and poverty combined
with HIV may have synergistic detrimental effects on long-
term neurocognitive outcomes. It is likely that a combined
approach incorporating social interventions, nutritional sup-
plements, and ART are necessary to fully optimize develop-
mental outcomes in HIV-infected children receiving ART.
HUU infants were recruited from a clinic with a majority
of clientele living within an informal settlement of Nairobi.
Most HUU infants in our study lived in one-room housing,
as did HIV-infected infants. Both groups had substantial
stunting (37.0 and 46.6%, respectively), compared with a
Kenyan national prevalence of 10% stunting among infants
aged less than 6 months (2014 Kenyan Demographic
Health Survey) [38]. Compared with the 2006 WHO refer-
ence population based in Ghana, India, Norway, Oman and
the US, HUU infants in our study had slightly later walking
unsupported (12.0 vs 13.0 months) [39]. Growth and devel-
opmental differences between this HUU group and national
and international norms may be partly attributable to socio-
economic differences.
Our study did not include an HIV-exposed uninfected
comparison group, and it is possible that infants with
better ART responses may have similar outcomes
compared with HIV-exposed uninfected children. HIV-
exposure is associated with higher morbidity, malnutri-
tion, and socioeconomic difficulties, such as HIV stigma,
orphan-hood or severe parental illness, and poverty, all
of which could contribute to delayed milestones [24, 40].
In cohorts from Uganda and Thailand, HIV-exposed
uninfected children had deficits in receptive language
and global cognitive functioning, respectively [30, 41].
We used parental self-report of a small number of
developmental milestones. A limitation of this study is lack
of detailed assessments of infant developmental functioning
for motor, social and language domains. In addition, the
HIV-infected and HUU cohorts were enrolled during differ-
ent timeframes (4–6 years apart). The two cohorts differed
in their catchment sites: HIV-infected infants were either
identified in hospital or maternal child health clinics (MCH)
in Nairobi; whereas HUU infants were recruited from a
single MCH clinic. There was overlap in the study clinical
officers who evaluated infants in each cohort, and we are
not aware of any programmatic differences that would have
led to different environmental stimulation between the co-
horts. We cannot rule out the possibility that subtle differ-
ences in data collection may have occurred between cohorts.
Strengths of this study included the intensive follow-up
(monthly), which allowed high precision for age at attainment
of milestones, growth, immune and virologic data. HIV-
infected infants in this study received empiric ART [42], but
were often immunocompromised, and thus these results are
generalizable to many HIV-infected infants in sub-Saharan
Africa who do not receive their HIV diagnosis until onset of
HIV symptoms have occurred.
Conclusions
In summary, we demonstrate partial restoration of neuro-
developmental outcomes in HIV-infected infants with im-
mune reconstitution and viral suppression by 6 months
post-ART, compared to uninfected peers. Growth status
during ART and immune and viral response to ART were
each independent cofactors for age at milestone attainment.
These data suggest that effective early ART is an important
intervention for ensuring optimal neurodevelopment in
HIV-infected infants, but that additional strategies, includ-
ing nutritional and social support, are likely needed.
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